Portal de Periódicos da CAPES

Intractable Withdrawal From Venlafaxine Treated With Fluoxetine

1997; Slack Incorporated (United States); Volume: 27; Issue: 2 Linguagem: Inglês

10.3928/0048-5713-19970201-05

1938-2456

William J Giakas, John M. Davis,

Neuroscience and Neuropharmacology Research

GRAND ROUNDSIntractable Withdrawal From Venlafaxine Treated With Fluoxetine William J Giakas, MD, , and , MD John M Davis, MD, , MD William J Giakas, MD and John M Davis, MD Psychiatric Annals, 2013;27(2):85–92Published Online:February 01, 1997https://doi.org/10.3928/0048-5713-19970201-05Cited by:22View Full TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995; 49:280-294. Google Scholar2. Montgomery SA Rapid onset of action of venlafaxine. Int Clin Psychopharmacol. 1995; 10:21-27. Google Scholar3. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 1994; 114:559-565. Google Scholar4. Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biol Psychiatry. 1984; 19:237-256. Google Scholar5. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994; 151:289. Letter. Google Scholar6. Philips SD. A possible paroxetine withdrawal syndrome. Am J Psychiatry. 1995; 152:645-646. Letter. Google Scholar7. Farah A Lauer TE. Possible venlafaxine withdrawal syndrome. Am J Psychiatry. 1996; 153:576. Letter. Google Scholar8. Grant KA The role of 5-HT3 receptors in drug dependence. Drug and Alcohol Dependence. 1995; 38:155-171. Google Scholar9. Bloch M, Stager S, Braun A Rubinow D. Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet. 1995; 357:57. Letter. Google Scholar10. Louie AK, Lannon RA1 Ajari LJ. Withdrawal reaction after sertraline discontinuation. Am J Psychiatry. 1994; 151:289, Letter. Google Scholar11. Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome? Biol Psychiatry. 1993; 33:851-852. Letters. Google Scholar12. Szabadi E. Fluvoxamine withdrawal syndrome. Br J Psychiatry. 1992; 160:283-284. Google Scholar13. Debattista C, Schatzberg A Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry. 1995; 152:1235-1236. Letter. Google Scholar14. Rosenstock HA Sertraline withdrawal in two brothers: a case report. Int Clin Peychopharmacol. 1996; 11:58-59. Google Scholar15. Oram K, Tanaka O, Kaneko S, Ishida M, Yasui N, Fukushima Y. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol. 1994; 9:131-133. Google Scholar16. Frost T, LaI S. Shock like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry. 1995; 152:810. Letter. Google Scholar17. Fava GA Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation. J CUn Psychopharmacol. 1995; 15:374-375. Google Scholar18. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol. 1994; 14:207. Google Scholar Previous article Next article FiguresReferencesRelatedDetailsCited by Brandt L, Heinz A and Henssler J (2022) Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy NeuroPsychopharmacotherapy, 10.1007/978-3-030-62059-2_28, (1173-1191), . (2021) Depression and Anxiety Disorders The Maudsley Prescribing Guidelines in Psychiatry, 10.1002/9781119870203.mpg003, (305-450) Brandt L, Heinz A and Henssler J (2021) Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy NeuroPsychopharmacotherapy, 10.1007/978-3-319-56015-1_28-1, (1-19), . Brandt L, Henssler J and Gutwinski S (2020) Entstehung, Merkmale, Prävention und Behandlung von Absetzphänomenen, InFo Neurologie + Psychiatrie, 10.1007/s15005-020-1293-6, 22:3, (26-35), Online publication date: 1-Mar-2020. Henssler J, Heinz A, Brandt L and Bschor T (2019) Antidepressant Withdrawal and Rebound Phenomena, Deutsches Ärzteblatt international, 10.3238/arztebl.2019.0355 Tihanyi B, Ferentzi E, Beissner F and Köteles F (2018) The neuropsychophysiology of tingling, Consciousness and Cognition, 10.1016/j.concog.2017.10.015, 58, (97-110), Online publication date: 1-Feb-2018. Shelton R (2018) Serotonin and Norepinephrine Reuptake Inhibitors Antidepressants, 10.1007/164_2018_164, (145-180), . Kotzalidis G, de Pisa E, Patrizi B, Savoja V, Ruberto G and Girardi P (2008) Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient, Journal of Psychopharmacology, 10.1177/0269881107081562, 22:5, (581-584), Online publication date: 1-Jul-2008. Haddad P and Anderson I (2018) Recognising and managing antidepressant discontinuation symptoms, Advances in Psychiatric Treatment, 10.1192/apt.bp.105.001966, 13:6, (447-457), Online publication date: 1-Nov-2007. Christmas D (2018) 'Brain shivers': from chat room to clinic, Psychiatric Bulletin, 10.1192/pb.29.6.219, 29:6, (219-221), Online publication date: 1-Jun-2005. (2005) Depression and anxiety The Maudsley 2005-2006 Prescribing Guidelines, 10.1201/b14455-5, (135-203), Online publication date: 12-May-2005. Reeves R, Mack J and Beddingfield J (2003) Shock-Like Sensations During Venlafaxine Withdrawal, Pharmacotherapy, 10.1592/phco.23.5.678.32198, 23:5, (678-681), Online publication date: 1-May-2003. Judge R (2001) Once-daily venlafaxine extended release (XR) vs. fluoxetine for the treatment of depression, Journal of Affective Disorders, 10.1016/S0165-0327(00)00257-3, 66:1, (95-96), Online publication date: 1-Sep-2001. Haddad P, Devarajan S and Dursun S (2016) Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke', Journal of Psychopharmacology, 10.1177/026988110101500210, 15:2, (139-141), Online publication date: 1-Mar-2001. Haddad P (2001) Antidepressant Discontinuation Syndromes, Drug Safety, 10.2165/00002018-200124030-00003, 24:3, (183-197), . Goldberg J (2000) NEW DRUGS IN PSYCHIATRY, Emergency Medicine Clinics of North America, 10.1016/S0733-8627(05)70119-X, 18:2, (211-231), Online publication date: 1-May-2000. BENAZZI F (1999) Fluoxetine for Clomipramine Withdrawal Symptoms, American Journal of Psychiatry, 10.1176/ajp.156.4.661a, 156:4, (661a-662), Online publication date: 1-Apr-1999. Gordon A (1999) Letters to the Editor, The Canadian Journal of Psychiatry, 10.1177/070674379904400117, 44:1, (91-96), Online publication date: 1-Feb-1999. McGahuey C, Delgado P and Gelenberg A (1999) Assessment of Sexual Dysfunction Using the Arizona Sexual Experiences Scale (ASEX) and Implications for the Treatment of Depression, Psychiatric Annals, 10.3928/0048-5713-19990101-10, 29:1, (39-45), Online publication date: 1-Jan-1999. Benazzi F (1998) SSRI discontinuation syndrome treated with fluoxetine, International Journal of Geriatric Psychiatry, 10.1002/(SICI)1099-1166(199806)13:6 3.0.CO;2-Y, 13:6, (421-422), Online publication date: 1-Jun-1998. Parker G and Blennerhassett J (2016) Withdrawal Reactions Associated with Venlafaxine, Australian & New Zealand Journal of Psychiatry, 10.3109/00048679809062742, 32:2, (291-294), Online publication date: 1-Apr-1998. Holroyd S and Durgee J (1998) Venlafaxine in Treatment Refractory Geriatric Depression, Clinical Gerontologist, 10.1300/J018v18n03_05, 18:3, (39-50), Online publication date: 4-Mar-1998. Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download • 6.7 MB Published online2/01/97